GlassScriptPhysician profile
Clarisse Tallah
NPI 1609225499
$1,238.51
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2022: $150 · 2023: $522 · 2024: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $144.00 | 2023-2024 | Mounjaro, Jardiance |
| Novo Nordisk INC | $139.10 | 2022-2024 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $123.82 | 2022-2024 | Rexulti, Abilify Maintena |
| Pfizer INC. | $118.40 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $116.64 | 2022-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Organon LLC | $103.33 | 2022-2024 | Nexplanon |
| Lupin INC. | $99.58 | 2019 | |
| Abbvie INC. | $60.03 | 2023-2024 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $58.07 | 2023-2024 | Farxiga, Breztri |
| Exact Sciences Corporation | $44.02 | 2023-2024 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $31.45 | 2024 | Ingrezza |
| Corium, LLC | $30.19 | 2023 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $30.19 | 2022-2024 | |
| Lundbeck LLC | $28.99 | 2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $27.32 | 2023-2024 | Jornay Pm |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $20.98 | 2024 | Veozah |
| Abbott Laboratories | $19.02 | 2024 | Freestyle Libre |
| Amgen INC. | $17.43 | 2024 | Repatha |
| Teva Pharmaceuticals USA, INC. | $13.54 | 2024 | Austedo Xr |
| Scynexis, INC. | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clarisse Tallah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.